معرفی
Dr David Sheridan is a hepatology researcher at Newcastle University specializing in hepatitis C virus pathogenesis, lipoviral particle dynamics, and metabolic interactions in chronic liver disease. His work spans clinical trials, mechanistic virology, and translational biomarker development with consistent publication output from 2007-2025.
His primary research interests focus on viral-host metabolic interactions, particularly how hepatitis C genotypes differentially manipulate cholesterol and lipoprotein pathways. Key contributions include characterizing lipoviral particle kinetics, identifying genotype-specific lipid biomarkers, and investigating apolipoprotein E's role in HCV pathogenesis and neuropsychiatric manifestations.
Analysis of his publication trends reveals strong emphasis on translational hepatology - bridging basic virology with clinical applications. His recent work includes phase II clinical trials of seladelpar for primary biliary cholangitis and development of gene-based fibrosis staging models. Major collaborations exist with Emeritus Professor Margaret Bassendine's research group at Newcastle.
- Scientific Awards: None explicitly mentioned in source material
Dr Sheridan's research program demonstrates sustained focus on viral hepatitis pathogenesis with increasing translational emphasis. His work on lipoviral particles has established important paradigms for understanding HCV's manipulation of host lipid metabolism, while recent clinical trial involvement indicates expanding impact on therapeutic development for cholestatic liver diseases.
